Latest Biotech News

Genentech reported superior phase III results for divarasib (KRAS G12C) in previously treated non-small-cell lung cancer, signaling a potential step-change versus the established class of KRAS...

AstraZeneca extended its China drug-development footprint with a new pact with CSPC Pharmaceutical covering two kidney disease candidates. The deal includes a $30 million upfront payment and is...

United Therapeutics moved to broaden its cell-therapy pipeline by paying $140 million to acquire Thymmune Therapeutics, targeting thymus-derived regenerative approaches. The upfront payment is...

Bellaseno accelerated development of its absorbable breast scaffold after a faster-than-expected pivotal trial trajectory in Australia and a new licensing deal with Johnson & Johnson’s Mentor...

Researchers unveiled small-molecule-controlled CRISPR systems designed to switch genome editing on only when dosing triggers are present. In a Science Translational Medicine paper, a team led by...

A research team reported molecular underpinnings for C5aR2, a complement receptor previously described as atypical in signaling behavior. The work, focused on C5aR2’s unique signaling and...

Neurovalens received FDA de novo clearance for Modius Spero, a wearable neuromodulation device intended to reduce PTSD symptoms. The treatment is designed for at-home use with 30-minute daily...

One Biosciences moved its single-cell profiling platform into clinical studies through an effort alongside Adcytherix. The collaboration advances OneMap, a single-nuclei RNA-seq-based assay...

Biopharma financings accelerated in the first half of 2026, with total funding reported at $59.76 billion across 567 deals—more than double the $29.53 billion raised in H1 2025. The year-over-year...

Celea Therapeutics raised $180 million to advance deupirfenidone into late-stage development for idiopathic pulmonary fibrosis. The PureTech-backed company said the venture round will fund a move...

Roche’s Genentech unit reported first-look Phase 3 results for divarasib in previously treated KRAS G12C non-small-cell lung cancer, using the head-to-head Krascendo 1 trial design. The company...

Aurenar’s V-Link received FDA breakthrough device designation after early clinical data suggested it reduced cerebral vasospasm by more than 40%, according to the report. The device is designed as...

United Therapeutics agreed to pay $140 million to acquire Thymmune Therapeutics, targeting preclinical and rare-disease regenerative cell therapies focused on thymus function. The upfront payment...

A research team led by Wang Yu at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences reported drug-controllable CRISPR genome editing systems in Science...

ATB Therapeutics presented data supporting its “atbodies” platform—antibody-peptide fusion constructs designed to address ADC off-target toxicities and narrower therapeutic windows. At the...

Researchers led by Associate Professor Marinka Zitnik at Harvard Medical School introduced COMPASS, an AI model designed to predict patient response to immune checkpoint inhibitor therapy. The...

AstraZeneca expanded its China partnership with CSPC Pharmaceutical through a kidney disease discovery pact totaling up to $1.7 billion. The report says AstraZeneca will pay a $30 million upfront...

Celea Therapeutics, backed by PureTech, raised $180 million to advance deupirfenidone for idiopathic pulmonary fibrosis. The reported venture round is intended to move the program into late-stage...

Genomics England and Lifebit will develop a trusted research environment to support cancer and rare disease studies. The partnership is described as creating secure, controlled digital workspaces...

Countable Labs reported progress on a PCR platform designed for single-molecule precision quantification, aiming to improve sensitivity and run-to-run reproducibility versus conventional...